Neuroblastoma Breakpoint Family Member NBPF12: Potential Drug Target

Target Name: NBPF12

NCBI ID: G149013

NBPF12

Neuroblastoma Breakpoint Family Member NBPF12: Potential Drug Target

Neuroblastoma, also known as a neurofibromatosis, is a type of cancer that affects the nervous system. It is characterized by the formation of tumors that develop from nerve cells, and can be treated with various medications, including chemotherapy and radiation therapy. However, despite these treatments, the survival rate for neuroblastoma remains high, and there is a need for more effective treatments.

One potential drug target for neuroblastoma is NBPF12, a gene that has been identified as a potential biomarker for the disease. NBPF12 is a gene that is located on chromosome 1p36 and has been shown to be expressed in a variety of tissues, including brain, muscle, and blood cells. It is also known as neuroblastoma breakpoint family member 12, or NB12, and is a member of the neuroblastoma breakpoint family, which is a group of genes that have been implicated in the development of neuroblastomas.

The neuroblastoma breakpoint family is a large gene family that includes over 20 genes that have been implicated in the development of neuroblastomas. These genes provide instructions for making proteins that are involved in a variety of cellular processes, including cell division, growth, and differentiation. Some studies have suggested that these genes may be involved in the development of neuroblastomas by causing changes in the way cells divide and grow.

One of the proteins that is known to be involved in the neuroblastoma breakpoint family is NBPF12. NBPF12 is a protein that is expressed in a variety of tissues and has been shown to be involved in the development and progression of neuroblastomas. It is thought to work by helping cells to divide and grow in an orderly fashion, and is also involved in the regulation of cell survival.

In addition to its role in cell division and growth, NBPF12 is also thought to be involved in the regulation of cell signaling pathways. It has been shown to be involved in the signaling pathway that regulates cell growth and differentiation, and has been shown to interact with a variety of proteins that are involved in this pathway.

Given the involvement of NBPF12 in the development and progression of neuroblastomas, it is a potential drug target for the treatment of this disease. Researchers are currently working to develop drugs that can inhibit the activity of NBPF12 in order to treat neuroblastomas. These drugs may work by inhibiting the ability of NBPF12 to regulate cell growth and division, or by inhibiting the activity of NBPF12 itself.

In addition to its potential as a drug target, NBPF12 is also being studied as a biomarker for the diagnosis and prognosis of neuroblastomas. Studies have shown that the expression of NBPF12 is often elevated in the brains of patients with neuroblastomas, and that levels of NBPF12 have been used as a biomarker to predict the prognosis of neuroblastomas.

Overall, NBPF12 is a promising drug target for the treatment of neuroblastomas. Further research is needed to fully understand the role of NBPF12 in the development and progression of neuroblastomas, and to develop effective treatments for this disease.

Protein Name: NBPF Member 12

The "NBPF12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBPF12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets